60 Days
Source:
اقتصاد سكاي نيوز عربية
Source: اقتصاد سكاي نيوز عربية
60 Daysاقتصاد سكاي نيوز عربية
Source: اقتصاد سكاي نيوز عربية
60 DaysReady to play
Ready to play
GlaxoSmithKline plans to raise approximately $6 billion by issuing high-rated U.S. bonds, aiming to refinance a $10.6 billion loan used to fund its acquisition of biotech company Novalent. The bonds will be offered in six tranches ranging from 3 to 30 years, with expected yields about 1.1 percentage points higher than the 30-year U.S. Treasury bonds. The size of the offering will depend on market demand. This move comes as the company seeks to capitalize on the booming investment-grade bond market in the United States after a quiet summer period.
Notice: This Is an AI-Generated Summary
Comments (0)